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The occurrence of SOX2-speciﬁc autoantibodies seems to be associated with an improved prognosis in patients with monoclonal
gammopathy of undetermined signiﬁcance (MGUS). However, it is unclear if SOX2-speciﬁc antibodies also develop in established
multiple myeloma (MM). Screening 1094 peripheral blood (PB) sera from 196 MM patients and 100 PB sera from healthy donors,
we detected SOX2-speciﬁc autoantibodies in 7.7% and 2.0% of patients and donors, respectively. We identiﬁed SOX2211−−230 as
an immunodominant antibody-epitope within the full protein sequence. SOX2 antigen was expressed in most healthy tissues and
its expression did not correlate with the number of BM-resident plasma cells. Accordingly, anti-SOX2 immunity was not related
to SOX2 expression levels or tumor burden in the patients’ BM. The only clinical factor predicting the development of anti-SOX2
immunity was application of allogeneic stem cell transplantation (alloSCT). Anti-SOX2 antibodies occurred more frequently in
patients who had received alloSCT (n = 74). Moreover, most SOX2-seropositive patients had only developed antibodies after
alloSCT. This ﬁnding indicates that alloSCT is able to break tolerance towards this commonly expressed antigen. The questions
whether SOX2-speciﬁc autoantibodies merely represent an epiphenomenon, are related to graft-versus-host eﬀects or participate
in the immune control of myeloma needs to be answered in prospective studies.
1.Introduction
SRY-related HMG box (SOX) is a superfamily of transcrip-
tion factors involved in embryonic development and stem
cell function [1]. Cancer cells share pathways regulating plu-
ripotency with embryonal stem cells [2], and some of the
transcription factors involved, including SOX2, have indeed
been identiﬁed as lineage survival oncogenes in epithelial
cancers [3]. The impact of SOX2-speciﬁc immunity on the
patient’s prognosis has been investigated in single solid
tumors [2]. However, the exact biological role of cancer-re-
lated SOX2-speciﬁc antibody and/or T cell responses has re-
mained unclear. Accordingly, some studies have suggested an
association with an improved prognosis while others have
foundnoassociationwiththepatients’outcomeorhaveeven
described a negative impact on the course of the disease [4–
6].
Monoclonal gammopathy of undetermined signiﬁcance
(MGUS) is a premalignancy converting to symptomatic
multiple myeloma (MM) at a rate of 1-2% of patients per2 Clinical and Developmental Immunology
year [7]. The prevalence of SOX2-speciﬁc antibodies in
MGUS patients has been linked to a decreased risk of pro-
gression to MM [8]. However, SOX2 is expressed not only in
MGUS but also in symptomatic MM [6], and it has remain-
ed unclear if and under which clinical conditions autoanti-
bodies against SOX2 also occur in established MM. More-
over, allogeneic stem cell transplantation (alloSCT) has been
suggested to break tolerance towards diﬀerent tumor anti-
gens in MM resulting in a clinically relevant graft-versus-
myeloma (GvM) eﬀect.The question is still open, however, if
alloSCT also inﬂuences the development of anti-SOX2 im-
munity in patients with established MM [9, 10]. To address
these issues, we performed a longitudinal analysis of SOX-
speciﬁc antibodies in patients with established MM.
2.MaterialandMethods
2.1. Patients. Patients were admitted for diagnostic purposes
and/or treatment to the University Medical Center Ham-
burg-Eppendorf. Repeated blood samples were obtained
during routine diagnostic procedures and all participants
provided informed consent prior to sample collection. A
total of 1094 peripheral blood (PB) plasma samples and 25
bone marrow (BM) samples were collected from 194 con-
secutive MM patients. In addition, 100 PB sera and 10 BM
samples were collected from healthy donors. Samples were
collected as previously described [11]. This study was con-
ducted in accordance with the declaration of Helsinki. The
protocol had received approval by the local ethics committee
(decision number OB-038/06).
2.2. Myeloma Cell Lines. Cell lines U266, RPMI 8266, LP1,
OPM2, NCIH929, MOPL8, KMS12BM, IM9, and EJM were
obtained from the German Collection of Microorganisms
andCellcultures(DSMZ,Braunschweig,Germany).Cellline
SK 007 was provided by the Ludwig Institute for Cancer Re-
search (LICR), New York branch. Cell lines were maintained
in RPMI 1640 and 10% fetal calf serum [12].
2.3. Proteins and Peptides. Full-length SOX2 protein and
control protein glutathione S-transferase (GST) were expres-
sed in a wheat germ system (Abnova, Taipei, Taiwan). Re-
combinantinﬂuenzanucleoprotein(FLU)producedinE.coli
was obtained from Imgenex (San Diego, Calif) and tetan-
us toxoid (TT) was provided by Chiron Behring (Marburg,
Germany). Control protein for FLU and TT antibody detec-
tion was GST expressed in E. coli (Cell Systems, St
Katharinen, Germany). 20mer SOX2 peptides (n = 31)
spanning the entire SOX2 sequence consisting of 317 amino
acids were obtained from Iris Biotech (Marktredwitz, Ger-
many).
2.4. Enzyme-Linked Immunosorbent Assay (ELISA). 96-well
plates were coated over night at 4◦C with recombinant pro-
tein or peptides diluted in PBS at a ﬁnal concentration of
1μg/mL, if not otherwise speciﬁed. Plates were blocked with
PBS containing 3% milk powder for two hours at room tem-
perature(RT).Serawerediluted1:100in5%milkpowderin
PBS(MPBS)and incubated for two hours at RT.A secondary
alkaline phosphatase-conjugated anti-human IgG antibody
(Southern Biotech, Birmingham, Ala) diluted 1:3000 in
MPBS was applied for one hour at RT. Detection reagent
para-nitrophenylphosphate (PNPP; Southern Biotech) was
added to the plates, and the phosphatase reaction took place
at RT for 30 minutes, before reaction arrest with 3N NaOH.
Speciﬁc absorption was measured at 405nm using a Sunrise
ELISA reader (Tecan, Crailsheim, Germany).
In the screening part of the study, a sample was consid-
ered antibody positive if the OD measured was higher than
the mean OD of 100 samples from healthy donors + 3 SD.
In addition, the OD was required to exceed the autologous
background signal measured with control protein GST by
at least 50%. In the titration part of the study, serial serum
dilutions were performed for antibody-positive samples, and
results obtained with GST protein were used as reference
values. For calculation of titers, regression analyses were per-
formed for the linear segment of the serum titration curves
for the patient sample and pooled sera of ﬁve representative
healthy donors. Titers were deﬁned mathematically as the
dilution at the intersection of both regression lines.
2.5. Real-Time PCR. Extraction of total RNA was performed
using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Re-
verse transcription and quantitative PCR were performed as
previously described [10]. The primer sequences for SOX2
were as follows: forward 5 -GCA CAT GAA CGG CTG GAG
CAA CG-3 , reverse 5 -TGC TGC GAG TAG GAC ATG
CTGTAG-3 .SampleswereanalyzedusingaLightCyclersys-
tem (Roche Diagnostics, Risch, Switzerland), and relative
quantiﬁcation was carried out by normalization against
GAPDH RNA.
2.6. Western Blot. Protein lysates were prepared using stan-
dardlysisbuﬀercontainingaproteaseinhibitorcocktail(Sig-
ma-Aldrich, Hamburg, Germany) and were subsequently
denaturated for 10min at 70◦C. Samples of lysates or recom-
binant protein containing 500μg and 300μg of total protein,
respectively, were separated using 4–12% Bis-Tris SDS-PAGE
gels (Invitrogen, Carlsbad, Calif) under reducing conditions.
Proteins were blotted on Hybond-ECL nitrocellulose mem-
branes (Amersham Biosciences, Piscataway, NJ), blocked
overnightat4◦CwithTop-Block(Fluka,Buchs,Switzerland).
Human sera were applied at a dilution ranging between
1:500 and 1:2000. An HRP-conjugated anti-human IgG-
Fcγ antibody (Sigma Aldrich) was used as secondary anti-
body at a dilution of 1:5000. β-Actin (Santa Cruz) served as
loading control.
2.7. Flow Cytometry. For the analysis of cytoplasmatic SOX2
protein expression, myeloma cell lines or bone marrow
mononuclear cells were ﬁrst stained using a CD138-FITC
monoclonal antibody (clone B-A38, BD Biosciences). Next,
cells were ﬁxed using FACS Lysing Solution (BD Biosciences)Clinical and Developmental Immunology 3
and were permeabilized using Permeabilizing Solution (BD
Biosciences). Cytoplasmic staining was performed applying
a PE-conjugated SOX2 antibody (clone IC2018P, R&D,
Abington, England) or an appropriate isotype control. Sam-
ples were analyzed using a FACSCalibur cytometer (BD Bio-
sciences) and FlowJo software (Tree Star, Ashland, Ore).
2.8. Epitope Prediction. Web-based prediction of potential
SOX2 antibody epitopes (http://www.cbs.dtu.dk/services/
BepiPred) was performed using the method published by
Larsen et al. [13].
2.9. Statistical Analysis. Statistical analyses were performed
using GraphPad software. The Mann-Whitney U test was
used to calculate diﬀerences between diﬀerent patient coho-
rts.Analysisofcovariancewasusedtoassesscorrelationsbet-
ween plasma cell count, SOX2 antibody titers, and SOX2
expression. Correlations between clinicopathological vari-
ables and occurrence of SOX2 antibodies were done by
Pearson’s χ2 test. Diﬀerences were regarded signiﬁcant if P<
0.05.
3. Results
3.1. SOX2 Is Expressed in Various Healthy Tissues and Malig
nant Myeloma Cells. SOX2 has been reported to be overex-
pressed in malignancies [14–16], and overexpression of
SOX2 has been associated with immunity towards autolo-
gous antigens in cancer patients [17]. Therefore, we ﬁrst ad-
dressed the expression of SOX2 in the BM of MM patients
compared to other tissues. To this end, we screened a wide
variety of normal tissues including 10 BM samples from
healthy donors as well as BM samples from 25 MM patients
for SOX2 expression by real-time PCR (Figure 1(a)).
We found SOX2 RNA to be ubiquitously expressed in all
tissues analyzed. SOX2 is an intronless gene, and, therefore,
this expression could also represent an artifact due to the
presence of genomic DNA within the samples. However, we
could rule out this possibility by showing that no SOX2 ex-
pression was detectable when the PCR was performed with
non-reverse-transcribed RNA samples (Figure 1(a)). Impor-
tantly, we did not detect any signiﬁcant diﬀerences in BM
expression of SOX2 between myeloma patients and healthy
donors (Figure 1(a)). To prove the presence of SOX2 on the
p r o t e i nl e v e l ,w eh a v ep e r f o r m e dﬂ o wc y t o m e t r ya n a l y s i so f
myeloma cell lines and of plasma cells of healthy donors, all
ofwhichwefoundpositiveforSOX2byRT-PCR.Important-
ly, all of the myeloma cell lines, all peripheral, and one of two
bone marrow-derived plasma cell samples were also found
positive for SOX2 on the protein level (Figure 1(b)). These
data demonstrate a strong correlation between expression on
the RNA level and protein expression as indicated by ﬂow
cytometry. As suggested by the comparable expression of
SOX2 in normal and malignant plasma cells and its broad
expression in diﬀerent healthy tissues, copy numbers of
SOX2 RNA as measured by quantitative PCR did not corre-
late with the percentage of myeloma cells within the BM of
our MM patients (Figure 1(c)).
3.2. Antibodies against SOX2 Recognize the Natural Protein
and Occur More Frequently in MM Patients Than in Healthy
Donors. We next screened a large number of sera (n = 1094)
consecutively collected from myeloma patients (n = 196) as
well as sera from healthy blood donors (n = 100) for anti-
body responses against SOX2. Analyzing a median number
of 5.4 (range 1–47) serum samples collected per patient dur-
ing a median follow-up period of 11.4 months (range 1–39
months), we found 7.7% (15/196) of MM patients and 2%
(2/100) of healthy donors to experience autoantibodies
againstSOX2(Figures2(a)and2(b)).Outofallsamplescon-
secutively collected from our myeloma patients, 2% (68/
1094) were positive for anti-SOX2 IgG antibodies. Overall,
myeloma patients showed a signiﬁcantly higher frequency
of anti-SOX2 antibodies than healthy controls (P<0.05,
Figure 2(c)).
To address the general seroreactivity of the included pa-
tients and donors against common microbial and viral anti-
gens, we screened all samples for the presence of antibodies
against inﬂuenza virus nucleoprotein (FLU) and tetanus to-
xoid (TT). Importantly we did not detect any diﬀerence in
thefrequencyofnaturallyoccurringorvaccine-inducedanti-
body responses between myeloma patients and healthy do-
nors(Figure 2(b)).Thisresultstronglysuggeststhatfrequen-
cy of anti-SOX2 immune responses in MM patients was not
inﬂuenced by a general hypogammaglobulinemia or B-cell
hyporeactivity.
Toconﬁrmthespeciﬁcityofourpatients’serumantibod-
ies, recognition of SOX2 was analyzed by western blot
(Figure 3(a)). We found that the IgG antibodies in the
patients’ sera recognized both the recombinant SOX2 pro-
tein and SOX2 protein expressed by a myeloma cell line
(U266) shown to be positive for SOX2 (Figure 3(a)). On the
otherhand,acontrolproteinandaSOX2-negativetumorcell
line (DLD-1) remained undetected by the patient serum.
3.3. SOX2211−230 Represents an Immunodominant Epitope Re-
cognized by Autoantibodies in Myeloma Patients. To further
address the speciﬁc target of the anti-SOX2 antibody respon-
ses, we mapped epitopes recognized using 31 overlapping
20mer peptides spanning the complete sequence of the anti-
gen. In one-third (5/15) of the patients we were not able to
detect any peptide-speciﬁc responses suggesting that the res-
pective antibodies might recognize conformational epitopes.
However, in themajority ofthe seropositive patients (53.3%)
SOX2-speciﬁc antibodies targeted amino acid region 211–
230 (Figure 3(b)). Other epitopes were much less frequently
recognized by the patient-derived anti-SOX2 IgG antibodies.
Using a hidden Markov prediction algorithm we predicted
the potential epitopes of target of a SOX2 speciﬁc-antibody
response (Figure 3(c)). Remarkably, the region with the
highest score was indeed the region preferentially targeted by
the majority of SOX2-speciﬁc antibody responses (211–230).
3.4. SOX2-Speciﬁc Autoantibodies Are Preferentially Induced
afterAllogeneic Stem Cell Transplantation. In order to under-
stand which clinical factors might be associated with the
development of anti-SOX2 antibodies in MM, we next cor-4 Clinical and Developmental Immunology
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Figure 1: (a) RT-PCR analysis of SOX2 expression normalized to GAPDH in human tissues. BM from MM patients (n = 25), healthy
donors (n = 15), myeloma cell lines (n = 10), and 20 human tissues (n = 1) was screened for SOX2 expression. Aqua dest. and non-
reverse-transcribed mRNA were used as negative controls. 20 organs were tested for the presence of contaminating DNA. The resulting
copy numbers (reverse-transcriptase-free) were normalized to GAPDH copy number of the respective tissue (cDNA). The mean value of all
reverse-transcriptase-freeresultswascalculatedandincludedasthereverse-transcriptase-free(RT-free)condition.(b)FACSanalysisofthree
MM patients’ BM, three BM of healthy donors, and three peripheral blood samples of healthy donors for SOX2 expression in gated CD138+
plasma cells. One BM sample (3) was found negative for SO2 protein expression. SOX2 expression was also found in 10 diﬀerent myeloma
cell lines. Isotype antibodies served as negative control for SOX2 expression. (c) Correlation analysis of SOX2 expression and percentage
of plasma cells in the BM of MM patients. No signiﬁcant association between SOX2 expression and the amount of plasma cells was found
(P = 0.6018, r2 = 0.03556). HD: healthy donor; MM: multiple myeloma; BM: bone marrow; PB: peripheral blood.
related a number of clinicopathological attributes of our pa-
tients with the presence or absence of such serological
responses. As expected from our observation of a missing as-
sociation between SOX2 antigen expression and the number
of BM-inﬁltrating plasma cells, we did not observe a cor-
relation between the presence of anti-SOX2 antibodies and
the tumor load in the respective patient (Figure 4(a)). Most
of the remaining clinicopathological parameters also lacked
an association with the appearance of a humoral response
against SOX2 (Table 1).
Since myeloma treatment, particularly stem cell trans-
plantation, has immune-modulating properties, we ﬁnally
investigated the relationship between therapeutic interven-
tions and the occurrence of SOX2-speciﬁc antibodies in the
myeloma patients. Remarkably, 92.6% (63/68) of all samples
found positive for anti-SOX2 antibodies were collected after
the patient had received alloSCT. In contrast, only 4.4% (3/
68), 0% (0/68), and 2.9% (2/68) of the SOX2 antibody-posi-
tive samples were derived from time points when the
patient had been treatment na¨ ıve, had only received conven-
tional chemotherapy, or had been treated with autologous
stem cell transplantation (autoSCT) as maximum therapy
(Figure 4(b)). Accordingly, 80.0% (12/15) of the anti-SOX2
antibody-positiveMMpatientshadreceivedalloSCTasmax-
imum therapy while only 13.3% (2/15), 0% (0/15) and 6.6%
(1/15), were treatment na¨ ıve or had been treated with con-
ventional chemotherapy or autoSCT as maximal therapy,
respectively (Figure 4(c)). Importantly, anti-SOX2 antibod-
ies are not likely to be a marker of an unspeciﬁc graft-versus-
host reaction, since none of the SOX2 antibody positive pa-
tients suﬀered from GvHD at any time point after alloSCT.
To further address the impact of alloSCT on SOX2-speci-
ﬁcimmunity,wescreenedsamplesfromthealloSCT,patients
taken before transplantation. From 10 available pre-alloSCT
samples 9 were found to be negative for SOX2 antibodies
prior to alloSCT and these patients had experienced a sero-
conversion at a median of 21.5 months (range 1–87 months)
aftertransplantation(Figure 4(d)).Thisobservationstrongly
suggests that immunological mechanisms induced by allo-
SCT may be capable of breaking tolerance towards SOX2.
Toinvestigateif,assuggestedbefore,SOX2antibodiesmay
protect from disease progression or recurrence [6], we
correlated SOX2 antibodies with the clinical remission status
of the patient. We found seropositive samples to be evenly
distributedbetweenpatientswithclinicalremission(56%)or
progressive disease (44%), respectively (see Supplementary
Figure 1 in Supplementary Material available online at doi:
10.1155/2011/302145). This ﬁnding suggests that there is no
immediate connection between the presence of anti-SOX2
humoral immunity and the clinical response of a given MM
patient.
4. Discussion
We hereby report SOX2 to be expressed in all tissues we anal-
yzed (Figure 1(a)), which is in contrast to previous studies
where SOX2 expression has been reported to be restricted
to certain tissues (among others neural, stem cell, or tumor
tissue) [3, 18]. However, the EMBL-EBI database (http://
www.ebi.ac.uk/gxa/gene?gid=P48431) which comprises a
meta-analysis of all gene expression data available for SOX26 Clinical and Developmental Immunology
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Figure 2: (a) Analysis of SOX2-speciﬁc IgG antibody responses in MM patients (n = 1094) and in healthy donors (n = 100). Results are
shown as optical density (OD) at 405nm. Horizontal bar represents the cut-oﬀ value for positivity (OD > 0.274). (b) Analysis of inﬂuenza-
nucleoprotein- (FLU-), tetanus-toxoid- (TT-) and glutathione-S-transferase- (GST-) speciﬁc antibody responses in the same collective of
MM patients and healthy donors. (c) Incidence of SOX2-speciﬁc antibody responses in the group of MM patients compared with the group
of healthy donors (7.7% versus 2.0%). We found signiﬁcantly more individuals with SOX2-speciﬁc antibody responses in the MM group
than in the healthy donor group (P<0.05).
reports expression in all parts of the human body and
in many disease states. In particular, this database reports
an expression of SOX2 in plasma cells and myeloma cells, as
conﬁrmed by our data (Figure 1).Inourcurrentstudy,SOX2
was not diﬀerentially expressed in the BM of healthy donors
when compared to the BM of MM patients, an observation
which would be in line with the latter analysis. While plasma
cells in general might indeed express comparably high levels
ofSOX2[19,20],webelievethatSOX2isbynomeanstumor
or myeloma speciﬁc. This assumption is further supported
by our ﬂow cytometry data (Figure 1(b)) which suggests a
similar expression of SOX2 in the BM of MM patients, in
MM cell lines, and in the BM and PB of healthy donors.
A single study has previously addressed SOX2-speciﬁc
antibodies in plasma cell disorders [6]. Spisek and colleagues
reported SOX2-speciﬁc antibodies in 23% of MGUS patientsClinical and Developmental Immunology 7
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Figure 3: (a) Analysis of speciﬁcity of the SOX2 targeted IgG antibody response. Serum from a patient found positive by ELISA was used
for western blot analysis and speciﬁcally recognized recombinant SOX2 and SOX2 from a SOX2-positive cell line (U266). In contrast, GST
and a SOX2-negative cell line (DLD1) remained unstained. ACTB was used as loading control. (b) Mapping of the epitopes of target of the
SOX2-speciﬁc antibody response in MM patients. Overlapping 20mer peptides (n = 31) spanning the complete SOX2 sequence were used.
Percentages of SOX2-antibody-positive patients for each epitope are given on the x-axis. Three patients recognized two or three epitopes. 8
patients had SOX2-speciﬁc antibodies only directed against the 20mer 22 (amino acids 211–230), and the antibodies of ﬁve patients did not
recognize any of the 20mers that were used. (c) Epitope prediction of the antibody response for the whole SOX2 protein sequence using a
hidden Markov prediction model. For each region probability scores are calculated. The grey area represents the main 20mers of target by
the SOX2 antibody response in MM patients.
andinnoneoftheMMpatientsscreened,whichisinopposi-
tion to our results. Here, we have shown that 7.7% of the
tested MM patients experience SOX2-speciﬁc humoralim-
munity. This discrepancy may have at least two diﬀerent
reasons. First, the comparably low number of MM patients
included (49 versus 196) may have limited the power of
the previous study to detect antibody-positive subjects. Sec-
ond, we describe herein an association between the applica-
tion of alloSCT and the development of anti-SOX humoral
responses. However, none of the patients described in the
previous study had received alloSCT, and, therefore, patients
with established MM developing anti-SOX2 antibody res-
ponses might have simply been missed.
Tothebestofourknowledgethisistheﬁrststudycharac-
terizing target epitopes of anti-SOX2 antibody responses. We
identiﬁedaregionoftheSOX2proteinwhichwastargetedby
the IgG antibodies of the vast majority of seropositive pa-
tients. Interestingly, our experimental results were in line
with the predictions of an online algorithm [13] naming
regions potentially recognized by anti-SOX2 antibody res-
ponses. Both approaches described SOX2211−230 as an im-
munodominant epitope. This ﬁnding might help to improve
SOX2-related immunomonitoring techniques in MM or
other diseases such as lung cancer but may also be of use for
the design of future immunotherapies targeting SOX2.
AlloSCTinducescomplexprocessesintherecipientduring
which autoantigens and/or tumor-associated antigens may
becomeimmunogenic[21,22].Itiswellknownthatimmune
responses, in particular T-cell responses, appearing after
alloSCT mediate the fatal graft-versus-host disease (GvHD)
[23]. On the other hand, donor-derived tumor-speciﬁc im-
mune reactions induced by transplantation are central for8 Clinical and Developmental Immunology
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Figure 4: (a) Correlation analysis between the percentage of plasma cells found in the BM of MM patients with the corresponding SOX2-
speciﬁc antibody titers. For some patients several samples from diﬀerent time points were analyzed. No signiﬁcant correlation was found
between these two parameters (P = 0.4826, r = 0.01153). (b) Treatment-dependent distribution of SOX2-positive samples and SOX2-
positive patients. 92% (63 of 68) of all SOX2-antibody-positive samples were collected after alloSCT, while 4% (3 of 68) and 2.9% (2 of
68) were collected at time of diagnosis or after chemotherapy, respectively. 80% of SOX2-antibody-positive patients had received alloSCT as
maximum treatment, while 13% (2 of 15) and 7% (1 of 15) were untreated or had received autoSCT, respectively. (c) Comparison between
SOX2-speciﬁc antibody titers before and after alloSCT. Mean values of titers for the respective patient prior and after alloSCT are shown.
From 12 SOX2-antibody-positive patients, pre-alloSCT samples were available for 10 patients. 9 of those patients were antibody negative
prior to alloSCT and subsequently seroconverted. SOX2-speciﬁc antibody titers were signiﬁcantly higher after alloSCT when compared to
pre-alloSCT titers (P<0.05).
the therapeutic potential of alloSCT [24]. Transplantation-
inducedimmunity,intheframeworkofagraft-versus-tumor
eﬀect,iscapableofattackingmalignantcells.Accordingly,we
and others have shown that alloSCT induces immune res-
ponses against tumor-speciﬁc or overexpressed antigens
[12]. In the case of the SOX2 antigen 80% of the seropositive
patients had been treated with alloSCT, and most of these
patients hadbeenantibody negative prior to transplantation.
Thus, we consider it likely that alloSCT might indeed induce
SOX2-speciﬁc immunity.
What is the biological meaning of the alloSCT-induced
SOX-speciﬁc immunity? First, anti-SOX2 immune responses
might indeed have an (positive or negative) eﬀect on tumor
progression.Atthistimewehavenoevidencesupportingthis
hypothesis since the occurrence of anti-SOX2 antibodies in
our myeloma patients was not related to the disease burden
or the remission status. Such an observation would be in line
with studies on patients with lung cancer which also failed
to detect any association of SOX-speciﬁc antibodies with the
prognosis of the patients [5, 25, 26].
On the other hand, anti-SOX2 immunity (maybe in con-
cert with immune responses against a multitude of other
autoantigens) might simply be a sign of autoimmune or even
alloimmune disease, that is, occurring in the framework ofClinical and Developmental Immunology 9
Table 1: Patient characteristics. Data are shown for all patients and
forthesubgroupofSOX2-seropositivepatients.LC:lightchain;HC:
heavy chain.
Parameter Total SOX2 seropositive Signiﬁcance
Sex n.s.
Male 115 9
Female 80 6
Age n.s.
>60 69 6
≤60 126 9
Karyotype∗ n.s.
Normal 83 7
Complex 15 0
del13q14 46 6∗
del17p13 12 3
t(4;14) 9 0
Not tested 30 0
LC isotype n.s.
Light lambda 62 6
Light kappa 100 7
HC isotype n.s.
IgG 167 13
IgA 18 0
Stage n.s.
I3 2 2
II 52 2
III 95 9
∗One patient was found to bear a 13q14 and a 17p13 deletion.
a GvHD reaction. In our current study, we did not detect
an association between the occurrence of GvHD and the pre-
sence of anti-SOX2 antibodies. In fact none of the SOX2-
antibody-positive patients who had been treated with allo-
SCT experienced acute or chronic GVHD.
Since on the one hand SOX2-speciﬁc immunity does not
seemtobeassociatedwithamorefavorablecourseofthedis-
ease and on the other hand it does not correlate with a graft-
versus-host reaction, the biological meaning of such an im-
mune response remains unclear. We will need to perform
prospective studies in MM in cohorts well balanced for treat-
ment and for stage of the disease to understand this immune
reaction. Eventually, knowledge gained through such studies
will help us to decide whether SOX2 represents a promising
prognostic or therapeutic target for patients with multiple
myeloma.
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